As AI models become versatile and adaptable across multiple contexts and industries, questions about inventive step sit at the heart of patent examination in China. The 2023 Patent Examination Guidelines (hereinafter referred to as ‘the Guidelines’) included several sessions dedicated to explaining how inventive step should be examined for AI-related inventions, featuring examples related to AI algorithms, big data, and user experience1. In the re-examination of Beijing ByteDance Network Technology Co. Ltd.’s application entitled “Method and apparatus for processing an image” (Application No. 201810734681.2)2, which was recognized as one of the Top 10 Re-examination Cases of 2025 by the CNIPA, the CNIPA focused on the following issue: when an existing…
- AI, China, China Patent Office, CNIPA, Inventions, Inventiveness, Patent, Patent Re-examination and Invalidation Department, Patent Re-examination Board, Top 10 IP Case
-
How a Secondhand Ground Brush Wiped Away a Chinese Patent
A Chinese robot vacuum company digs up “hidden evidence” to successfully invalidate a patent owned by its biggest competitor. Highlights Background With the growth of online shopping, it is easier than ever to provide evidence of a sale when the product is still being sold on the market. But what if the product is no longer being sold? It’s much more challenging to prove the original disclosure date for a secondhand item, especially in a jurisdiction like China, which has very stringent notarization and legalization1 requirements for introducing evidence into a proceeding. The case below demonstrates an example of how one major Chinese robot company successfully dug up and introduced…
-
Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the biggest markets in the world. Any shortening of the patent term for this key semaglutide patent in China could cause an immediately shift in the Chinese Ozempic market (not to mention directly impacting Novo Nordisk). Novo Nordisk’s Semaglutide Patent in China On September 5, 2022, the China National Intellectual Property Association (China’s patent administrative office,…



